Safety and efficacy of vorapaxar in secondary prevention of atherosclerotic disease: A meta-analysis of randomized control trials

International Journal of Cardiology

Volumn 227, Issue , 2017, Pages 617-624

  Sharma, Abhishek ^a,i   Helft, Gérard ^b   Garg, Aakash ^c   Agrawal, Sahil ^d   Chatterjee, Saurav ^e   Lavie, Carl J ^f   Goel, Sunny ^g   Mukherjee, Debabrata ^h   Marmur, Jonathan D ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d ST LUKE S UNIVERSITY HEALTH NETWORK   (United States)

^e Cardiovascular Diseases   (United States)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g MAIMONIDES MEDICAL CENTER   (United States)

^h TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

ⁱ Institute of Cardiovascular Science and Technology   (United States)

Author keywords

Atherosclerotic vascular disease; Vorapaxar

Indexed keywords

PLACEBO; VORAPAXAR; ANTITHROMBOCYTIC AGENT; LACTONE; PYRIDINE DERIVATIVE;

ARTICLE; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; META ANALYSIS; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REOPERATION; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW; TREATMENT RESPONSE; PROCEDURES; TREATMENT OUTCOME;

ATHEROSCLEROSIS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LACTONES; MULTICENTER STUDIES AS TOPIC; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 85003967073     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.10.088     Document Type: Article

References (34)

1. [1] WHO, Atlas of Heart Disease and Stroke. 2004, World Health Organization, Geneva.
2. [2] American College of Cardiology, American Heart Association Task Force on Practice Guidelines, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Clinical Chemistry, 2014 AHA/ACC guideline for the Management of Patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 64:24 (Dec 23 2014), e139–e228.
3. [3] ESC Committee for Practice Guidelines, ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 32:23 (Dec 2011), 2999–3054.
4. [4] Anderson, J.L., Adams, C.D., Antman, E.M., et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the Management of Patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123 (2011), e426–e579 (Erratum, Circulation 2011;123(22):e627).
5. [5] Bhatt, D.L., Fox, K.A., Hacke, W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354:16 (Apr 20 2006), 1706–1717.
6. [6] Davey, M.G., Lüscher, E.F., Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature 216:5118 (Dec 2 1967), 857–858.
7. [7] Andersen, H., Greenberg, D.L., Fujikawa, K., et al. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc. Natl. Acad. Sci. U. S. A. 96:20 (Sep 28 1999), 11189–11193.
8. [8] Yano, Y., Ohmori, T., Hoshide, S., et al. Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. Eur. Heart J. 29:14 (Jul 2008), 1729–1738.
9. [9] Kosoglou, T., Reyderman, L., Tiessen, R.G., et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur. J. Clin. Pharmacol. 68:3 (Mar 2012), 249–258.
10. [10] US Food and Drug Administration, FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm396585.htm (Accessed June 17, 2014).
11. [11] Morrow, D.A., Braunwald, E., Bonaca, M.P., et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366:15 (Apr 12 2012), 1404–1413.
12. [12] Tricoci, P., Huang, Z., Held, C., et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N. Engl. J. Med. 366:1 (Jan 5 2012), 20–33.
13. [13] Becker, R.C., Moliterno, D.J., Jennings, L.K., et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373:9667 (Mar 14 2009), 919–928.
14. [14] Goto, S., Yamaguchi, T., Ikeda, Y., et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH 530348 for non-ST-segment elevation acute coronary syndrome. J. Atheroscler. Thromb. 17:2 (Feb 26 2010), 156–164.
15. [15] Moher, D., Liberati, A., Tetzlaff, J., PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151:4 (Aug 18 2009), 264–269.
16. [16] Valgimigli, M., Tricoci, P., Huang, Z., et al. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am. J. Cardiol. 114:5 (Sep 1 2014), 665–673.
17. [17] Whellan, D.J., Tricoci, P., Chen, E., et al. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J. Am. Coll. Cardiol. 63:11 (Mar 25 2014), 1048–1057.
18. [18] Bonaca, M.P., Scirica, B.M., Braunwald, E., et al. Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial. J. Am. Coll. Cardiol. 64:22 (Dec 9 2014), 2309–2317.
19. [19] Bonaca, M.P., Scirica, B.M., Braunwald, E., et al. New ischemic stroke and outcomes with vorapaxar versus placebo. Results from the TRA 2P-TIMI 50 trial. J. Am. Coll. Cardiol. 64:22 (Dec 9 2014), 2318–2326.
20. [20] Scirica, B.M., Bonaca, M.P., Braunwald, E., et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2ÅãP-TIMI 50 trial. Lancet 380:9850 (Oct 13 2012), 1317–1324.
21. [21] Bonaca, M.P., Bhatt, D.L., Cohen, M., Steg, P.G., Storey, R.F., Jensen, E.C., Magnani, G., Bansilal, S., Fish, M.P., Im, K., Bengtsson, O., Oude Ophuis, T., Budaj, A., Theroux, P., Ruda, M., Hamm, C., Goto, S., Spinar, J., Nicolau, J.C., Kiss, R.G., Murphy, S.A., Wiviott, S.D., Held, P., Braunwald, E., Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 372:19 (May 7 2015), 1791–1800.
22. [22] Wallentin, L., Becker, R.C., Budaj, A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361 (2009), 1045–1057.
23. [23] Brar, S.S., ten Berg, J., Marcucci, R., et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J. Am. Coll. Cardiol. 58:19 (Nov 1 2011), 1945–1954.
24. [24] Angiolillo, D.J., Capranzano, P., Goto, S., et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur. Heart J. 29 (2008), 2202–2211.
25. [25] Youn, Y.J., Lee, J.W., Ahn, S.G., Lee, S.H., et al. Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease. Am. Heart J. 167:2 (Feb 2014), 241–248.
26. [26] Park, K.W., Kang, S.H., Park, J.J., et al. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen). JACC Cardiovasc. Interv. 6:9 (Sep 2013), 932–942.
27. [27] Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357:20 (Nov 15 2007), 2001–2015.
28. [28] Diener, H.-C., Bogousslavsky, J., Brass, L.M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364:9431 (Jul 24-30 2004), 331–337.
29. [29] Coughlin, S.R., Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost. 3:8 (Aug 2005), 1800–1814.
30. [30] Kato, Y., Kita, Y., Hirasawa-Taniyama, Y., et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur. J. Pharmacol. 473 (2003), 163–169.
31. [31] Kataoka, H., Hamilton, J.R., McKemy, D.D., et al. Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells. Blood 102:9 (Nov 1 2003), 3224–3231.
32. [32] McNamara, C.A., Sarembock, I.J., Gimple, L.W., et al. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J. Clin. Invest. 91:1 (Jan 1993), 94–98.
33. [33] Chatterjee, S., Sharma, A., Mukherjee, D., PAR-1 antagonists: current state of evidence. J. Thromb. Thrombolysis 35:1 (Jan 2013), 1–9.
34. [34] Capodanno, D., Bhatt, D.L., Goto, S., et al. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials. J. Thromb. Haemost. 10:10 (Oct 2012), 2006–2015.